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the chi-square test CONCLUSIONS: Despite the fact that clusters are generated
from different approaches and have no similar characteristics, a plausible corre-
spondence seems to develop between them. Thus, our investigations may help in
identifying countless promising market strategies facilitating the access of new
drugs according to UK regional standards.
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OBJECTIVES: To examine inequalities in health service utilisation in urban Paki-
stan. This analysis investigates how household economic status, duration of illness
and distance to a provider influence health service utilisation in Pakistan.
METHODS: The study uses data from the Pakistan Socioeconomic Survey (PSES)
and analysis is based on 1,407 individuals who belong to 855 urban households.
Health care providers are classified into public hospitals, other public providers,
private doctors/clinics and other private providers. Household economic status is
measured by a wealth index constructed using data from the survey on ownership
of durable assets and housing conditions. Principal components analysis (PCA) is
used to construct the index. Multinomial logistic regression is used to investigate
the effects of various characteristics of individuals/households on health service
utilisation in Pakistan. RESULTS:Overall, 79.6% of those reporting any health com-
plaint sought health care. A large gap in health service utilisation exists between
poorest patients (60.5%) and richest patients (84.9%). Almost three-fourth patients
visited private providers; 57.3% visited private doctors/clinics and 15.7% visited
other private providers. The remaining one-fourth patients visited public providers
(19.7% visited public hospitals and 7.2% other public providers). Multinomial logis-
tic regression reveals that poorest patients are significantly more likely (p0.10) to
visit public hospitals whereas patients of poorest, poor, middle and rich house-
holds are significantly less likely to visit private doctors/clinics compared to mem-
bers of richest households controlling for other factors such as education, occupa-
tion, duration of illness, distance to a provider and residence. An additional day of
illness significantly (p0.01) increases the likelihood of visiting public hospitals
and private doctors/clinics. The distance travelled to visit a provider shows a sig-
nificant positive (p0.01) and negative association with visiting public hospitals
and other private providers respectively. CONCLUSIONS: Large gaps exist in health
service utilization in urban Pakistan.
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OBJECTIVES: Generate preliminary estimates of active health care professional
(HCP) time required /potential time and cost savings between SC vs. IV rituximab
processes at the care unit and pharmacy in sites participating in T&M sub-study to
MO25455 trial (ClinicalTrials.gov identifier NCT01461928). METHODS: As part of an
ongoing multi-country, multi-centre, prospective, T&M study run as a sub-study to
MO25455, one interview with a nurse and pharmacy member was conducted per
site, using a structured questionnaire to elicit practice pattern flow and time esti-
mates for rituximab-related tasks for both IV and SC processes. Estimates of SC
injection time were obtained from the Spark-Thera Phase Ib trial (BP22333) (in the
absence of staff-elicited time estimates). Estimated total time/cost was calculated
as the sum of individual task times/costs. UK salary costs were assumed. Results
were pooled and descriptive statistics were calculated. RESULTS:Median total HCP
time for IV vs. SC processes was estimated at 57 and 26 minutes, respectively,
equivalent to approximately £79 and £37 (estimated 54% reduction with SC). For IV,
process time is taken up by premedication (27%) and rituximab pharmacy recon-
stitution (18%), with the remaining 55% distributed across other care unit tasks. For
SC, premedication (57%), injection (24%) and rituximab pharmacy dispensing (19%)
constitute the whole process. Potential time savings are expected because of avoid-
ing tasks related mainly to infusion line (dis)connection, infusion initiation/dose
escalations, and IV pharmacy reconstitution, which is only partially being replaced
by SC injection. CONCLUSIONS: A switch from IV to SC rituximab potentially re-
sults in important care unit and pharmacy time savings to be reinvested in improv-
ing overall patient care. Patients could potentially be moved out of the chemother-
apy care unit to receive SC administration in other settings and free up valuable
chair time, thereby increasing the unit’s throughput and overall efficiency. Data of
the T&M study is awaited.
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OBJECTIVES: To compile pharmaceutical expenditure in Greece by financing
scheme and type of provider, in order to investigate areas that cost containment
measures could be monitored effectively. METHODS: The method used for the
estimation of pharmaceutical expenditure is based on the System of Health Ac-
counts 2011 set by OECD, EUROSTAT, and WHO, taking into consideration the
national needs for data reporting both in outpatient and inpatient settings. Data
were reported by type of provider, including hospital pharmacies, Social Security
Funds (SSF) pharmacies, private pharmacies and local authorities social pharma-
cies as well as by financing schemes, including SSFs, private payments and NHS
payments. Additionally, pharmaceutical data are analysed using the new interna-
tional classification of Factors of Health Care Provision. Estimates were obtained
for 2009 & 2010. RESULTS: Total pharmaceutical expenditure-TPE (outpatient &
inpatient) in Greece, decreased by 9,3% between 2009 & 2010. Pharmaceutical out-
patient expenditure covered by SSF was estimated at €5.1 bl for 2009 (2.2% of GDP)
and €4.46 bl for 2010 (2% of GDP). Less than 8% of outpatient pharmaceutical ex-
penses covered by SSF, concern pharmaceuticals dispensed by NHS & SSF pharma-
cies. These public pharmacies dispense expensive pharmaceuticals (for serious
and chronic diseases) at significantly lower prices than private pharmacies. Inpa-
tient pharmaceutical expenses decreased by 9,1% (€1.2 bl in 2009 and €1.1 bl in
2010), representing 15.3% of total pharmaceutical expenditures (outpatient and
inpatient), a proportion similar to the mean of other EU countries estimated at
about 17%. Measures to control the volume of consumption were recently intro-
duced via e-prescribing and the set up of controlling mechanisms. CONCLUSIONS:
Reductions in pharmaceutical expenditure are correlated mainly to price reduc-
tions and less to a decrease in volume of consumption. Measures concerning phar-
maceutical cost containment have to be reorganised not only concerning price and
volume but also concerning new –innovative ways of distributing pharmaceuticals.
PHS85
THE COST OF PUBLIC CANCER PREVENTION IN ALBERTA
Jacobs P1, Moffatt J2
1Institute of Health Economice, Edmonton, AB, Canada, 2Institute of Health Economics,
Edmonton, AB, Canada
OBJECTIVES: We provide an estimate of public expenditures on cancer prevention
in Alberta. Our estimate covers all three levels of government – federal, provincial,
and municipal. METHODS: Public cancer prevention is a government activity
whose purpose is to expressly reduce the future incidence of cancer. As part of
a wider initiative, we conducted a survey of ministries, in search of all programs
whose express purpose was to promote health and prevent illness. We searched
web pages, ministry annual reports and federal and provincial budget papers. We
collected data on program type, type of intervention, and program cost. We then
verified the results with each ministry. We sorted the data by risk factors, and
selected those risk factors that were related to cancer. RESULTS: Expenditures for
those risk factors that are related to cancer are shown in Table 1. In total expendi-
tures on these risk factors were $206. Of this, about two-thirds were expenditures
that were incurred by non-health, provincial ministries. The risk factor with the
highest preventive expenditures was environmental health. CONCLUSIONS: In
Alberta, all levels of government spent $206 per person on risk factors that can
prevent cancer, mostly in the long run. Without a cost – effectiveness analysis, we
cannot say that this amount is too much or too little. However with this data, and
a cost effectiveness analysis, we can in fact say whether we are spending too much
or too little.
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OBJECTIVES: To describe resource utilization and costs associated with treating
surgically managed non-small-cell lung cancer (NSCLC) patients in Ontario, Can-
ada; to compare characteristics and average costs of patients treated with adjuvant
therapy to surgery alone; and to compare resource utilization and costs across
health care regions. METHODS: A population-based retrospective cohort study of
surgically resected NSCLC patients, diagnosed from Ontario Cancer Registry be-
tween 2004 and 2006, was identified using administrative health care data. Patients
were followed for four years from date of surgery (to represent the cohort imme-
diately affected by the change in clinical practice -- recommended adjuvant cispla-
tin-based treatment). Cost estimates (2001 CAN dollars) were derived from admin-
istrative data and the literature. RESULTS: Patients who received adjuvant
chemotherapy in addition to surgery were younger and had a less severe burden of
co-morbid disease than patients treated with surgery alone (p0.001). Geographic
variation was found with respect to age, Charlson score, and socioeconomic status.
Rates of chemotherapy, the proportion of patients who received any imaging
scans, hospitalizations, specialist visits, emergency room visits, mean number of
imaging scans, general physician visits, and blood transfusions all varied signifi-
cantly among geographic regions. The average cost of a patient treated with sur-
gery and adjuvant chemotherapy was $36,617.70 and was significantly higher than
the average cost of a patient treated with surgery alone ($29,071.60) (p0.0001).
Among regions, the average cost of patients treated with chemotherapy was sim-
ilar, while the average cost of patients treated with surgery alone varied signifi-
cantly (p0.0008). CONCLUSIONS: Differences exist in the average cost of treating
a resectable NSCLC patient with surgery and adjuvant chemotherapy in compari-
son with surgery alone. This phase IV population-based study demonstrates a
similar cost per patient as evidenced in the randomized controlled trials. Under-
standing why these patients incur higher average costs is important with respect to
delivering cost-effective treatment.
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